Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1G | O43497 | 4/20 | 0.61 |
| ▸ | CACNA1H | O95180 | 4/20 | 0.61 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.53 |
| ▸ | C5AR1 | P21730 | 2/20 | 0.52 |
| ▸ | CCR8 | P51685 | 4/20 | 0.51 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.51 |
| ▸ | DRD2 | P14416 | 1/20 | 0.49 |
| ▸ | DRD4 | P21917 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6496325 | 0.90 | KDM4E (0.58) | CACNA1GCACNA1HOPRM1CYP3A4CYP2D6 | |
| SCHEMBL6496417 | 0.89 | KDM4E (0.61) | CACNA1GCACNA1HOPRM1CYP3A4CYP2D6 | |
| SCHEMBL6495959 | 0.89 | CYP3A4 (0.53) | CACNA1GCACNA1HOPRM1CYP3A4CYP2D6 | |
| SCHEMBL7066869 | 0.88 | OPRM1 (0.51) | CACNA1GCACNA1HOPRM1CYP3A4CYP2D6 | |
| SCHEMBL6501702 | 0.87 | CYP3A4 (0.56) | CACNA1GCACNA1HOPRM1CYP3A4CYP2D6 | |
| SCHEMBL6505921 | 0.87 | C5AR1 (0.57) | CACNA1GCACNA1HOPRM1CYP3A4CYP2D6 | |
| SCHEMBL6508675 | 0.87 | CYP3A4 (0.52) | CACNA1GCACNA1HOPRM1CYP3A4CYP2D6 | |
| SCHEMBL6507890 | 0.82 | CYP3A4 (0.49) | CACNA1GCACNA1HOPRM1CYP3A4CYP2D6 | |
| SCHEMBL7066463 | 0.82 | CYP3A4 (0.62) | OPRM1CYP3A4CYP2D6C5AR1CCR8 | |
| SCHEMBL7070692 | 0.80 | OPRM1 (0.57) | OPRM1CYP3A4CYP2D6C5AR1CCR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050143372-A1 | Compounds, pharmaceutical compositions and methods of use therefor | MILLENNIUM PHARMACEUTICALS, INC. | 2005-06-30 | — | — | US | disclosed |
| WO-2003037271-A2 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREFOR | MILLENNIUM PHARMACEUTICALS,INC. (US) | 2003-05-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050143372-A1 | Compounds, pharmaceutical compositions and methods of use therefor | CCR8, CCL11, CCR5 | CACNA1G 4005/4885CACNA1H 3661/4885OPRM1 494/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.